There is no cure for Parkinson's today, and no approved drug has been shown to slow it. Every approved treatment eases symptoms. Our view: a cure will need two parts: stopping the spread of the misfolded protein alpha-synuclein early, and replacing the dopamine cells already lost.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Treatment decisions belong with a neurologist, ideally a movement-disorder specialist.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your neurologist.
Could new dopamine cells, paired with a treatment that truly stops alpha-synuclein from spreading, stay healthy for decades instead of years? Such a treatment does not yet exist. It could be tested first in animals given a graft and the spreading protein.
What would prove it wrong: if stem-cell grafts stay free of alpha-synuclein clumps for 15 years or more without added protection, or if blocking the protein does not reduce its spread into grafts in animals.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
In monkeys given Lewy body extract from people with Parkinson's, boosting a protein called LAMP2A (part of the cell's waste-clearing system) protected dopamine-making nerve cells, delayed harmful alpha-synuclein build-up, and helped movement and thinking tests. The authors call it preliminary preclinical evidence. It was tested only in animals, not in people.
In 57 people with early Parkinson's, the company reported better motor and non-motor scores than placebo in a subgroup of 27 people with higher platelet counts, a possible inflammation marker. The result is from an exploratory subgroup, was shown as a conference poster, and needs a larger trial. No serious side effects were reported. Biovie has asked the FDA for a meeting to plan a Phase 3 trial.
Mayo Clinic is testing very low-dose radiation aimed at brain inflammation in about 20 people aged 45 to 70 with early Parkinson's. The main measure is a 7-point drop in the motor score at six months. Enrollment is by invitation only. This is a trial plan, with no results.
In 52 people with Parkinson's who had just received deep brain stimulation implants, follow-up programming done by video was as good as in-person visits for motor symptoms at 90 days (median difference -2.5 points, 95% range -9.0 to 2.0, within the 5-point margin set in advance). Serious side effects were similar and there were no deaths. It was a small, open-label trial and covers only the first 3 months. It is about how care is delivered, not a new treatment.
Xellsmart reported that in nine people with moderate to advanced Parkinson's, the cell transplant was well tolerated, with no serious side effects judged related to it. At six months the motor score (off medication) improved by more than 30 points on average, and daily diaries showed over 5 more hours of good "on" time. There was no control group, the data are company-reported, and a Phase 2 trial is still running.
First patient dosed in a Phase 1b trial of an oral drug that blocks USP30, an enzyme that slows the clearing of damaged mitochondria. Up to 36 adults with mild to moderate Parkinson's will take it or placebo for 28 days. It tests safety and whether the drug reaches the brain. First data are expected in 2027.
In 34 people with Parkinson's who used inhaled levodopa during an "off" episode, motor scores improved within 30 minutes (UPDRS-III 25.9 to 11.2). By 90 minutes about 67% of the motor benefit remained versus 100% of the non-motor benefit, such as mood and pain symptoms. It was an open-label, after-the-fact analysis of a small study, so the authors call it a hint to confirm.
In 410 people with early Parkinson's in Norway, 52 weeks of this vitamin B3 supplement (500 mg twice a day) did not help. Total symptom scores rose 2.45 points on the supplement and fell 0.27 on placebo (difference 2.72 points, p = .02, favoring placebo), and non-motor symptoms worsened more on it. Serious side effects were fewer on the supplement (8.3% vs 14.1%). The authors say the results do not support it as a disease-modifying treatment.
In 341 people with Parkinson's and "off" time, the 150 mg daily dose cut daily off time by 0.61 hours more than placebo after 12 weeks (1.56 vs 0.95 hours, p = .035). Headache, nausea and insomnia were more common on the drug; no serious side effects in the 150 mg group. The drug works without targeting dopamine. The company (Cerevance) says it will talk to the FDA about next steps; nothing has been filed or approved.
Small safety trial: 8 people per group (6 on drug, 2 on placebo), 7 days of dosing, in healthy older adults and people with Parkinson's. Blood tests of brain-derived particles showed changes in insulin signaling and inflammation markers that faded after dosing stopped. The trial was not designed to test whether it helps symptoms, so this shows only an early signal.
12 of 13 evaluable people stayed stable on motor scores over 12 months, with good safety. It was small, open-label (no placebo group) and company-reported, so it shows promise only.
First selective D1/D5 dopamine agonist, approved for early Parkinson's and as an add-on to levodopa. Launch expected October 2026.
Tests whether the anti-inflammatory drug adalimumab can delay Parkinson's in people with REM sleep behavior disorder, before movement symptoms start.
42 people, 32 finished. Symptom scores worsened less on the supplement than on placebo, and a brain scan showed less decline. The trial was small and exploratory, with no correction for multiple tests, so it needs a larger trial.
40 people got three infusions or placebo. The infusions looked safe, but no benefit was shown after accounting for multiple tests.
30 people, 21 days. Mostly mild side effects (nasal irritation, nosebleeds) and no low blood sugar. No clear benefit over placebo; a larger trial is needed.
A brain-penetrating drug that boosts the GCase enzyme lowered a toxic byproduct in spinal fluid, a sign the target was hit. Extension ends September 2026.
The GBA-targeted drug missed its goals and was discontinued for Parkinson's.
An off-the-shelf, frozen stem-cell dopamine product reported 12-month outcomes at ISSCR 2026, adding to the evidence for cell replacement.
Progressive aerobic exercise did not show a protective effect on an MRI marker of brain-cell damage, but it made levodopa work better.
Didn't slow progression in 648 people with early Parkinson's despite over 90% LRRK2 inhibition. Discontinued for idiopathic Parkinson's.
The iPS-cell therapy is priced at about ¥55.3 million per patient. Treatment expected to begin in fall 2026.
World's first approval of an iPS-cell-derived therapy for Parkinson's. Conditional, time-limited approval for 7 years.
Protocol published for a 330-person trial of high-dose ambroxol, a cough medicine that boosts the GBA1 enzyme, with patients grouped by GBA1 status.
A trial in early Parkinson's at 152 sites, with two years of treatment. First alpha-synuclein antibody in Phase 3.
First patient treated in the first Phase 3 trial of a stem-cell-derived dopamine neuron therapy.
The GLP-1 diabetes drug didn't slow Parkinson's over two years in 194 people, despite a promising Phase 2.
Less worsening of movement symptoms than placebo at 12 months in 156 people, but nausea affected 46%.
Symptom control keeps getting better: new pills, 24-hour pumps, and now cell replacement. A drug that slows the disease is still missing.
The world's first treatment made from iPS (reprogrammed stem) cells. Lab-grown dopamine-cell precursors are transplanted into the brain. Japan approved it for 7 years while more evidence is gathered, and national insurance covers it from May 2026 (about ¥55 million, roughly $350,000).
A once-daily pill and the first to selectively target D1/D5 dopamine receptors. In the TEMPO trials it improved movement scores and added "on" time without troublesome extra movements. It eases symptoms but doesn't slow the disease. U.S. launch is expected in October.
In Phase 1, benefits were still holding at 36 months with no treatment-related serious side effects. The Phase 3 exPDite-2 trial compares it with sham surgery in 102 patients.
The first antibody against alpha-synuclein to reach Phase 3. The two-year trial tests whether clearing the misfolded protein slows the disease. Completion is expected in 2029.
Levodopa infused under the skin around the clock from a small wearable pump, for steadier control than pills. Europe, Canada and Australia approved it first.
In 648 people with early Parkinson's, it blocked over 90% of LRRK2 activity but didn't slow the disease. A smaller study in LRRK2 gene carriers continues, with data in 2027.
| Treatment | For | What it does |
|---|---|---|
| Levodopa (U.S. 1970) | Nearly everyone | The brain turns it into dopamine. Still the most effective symptom treatment. |
| Dopamine agonists (incl. tavapadon, 2026) | Early disease, add-on | Mimic dopamine at its receptors. |
| MAO-B and COMT inhibitors | Add-on | Make each levodopa dose last longer. |
| Deep brain stimulation, focused ultrasound | Selected patients | Calm overactive brain circuits that cause tremor and movement swings. |
| Continuous infusions (Vyalev 2024, Onapgo 2025) | Advanced disease | Deliver medicine all day for fewer "off" periods. |
No supplement prevents or cures Parkinson's. Exercise has the strongest evidence of anything outside a pharmacy. We rate each by the strength of human evidence.
People who exercise more through midlife are diagnosed with Parkinson's less often in long-term studies.
Caffeine drinkers show lower Parkinson's rates in many population studies. That isn't proof that caffeine protects.
Not a supplement, but the clearest environmental step. Use protective gear with farm, lawn and industrial chemicals.
Improves movement, balance and mood in trials. A 2026 trial didn't find a brain-protecting effect on MRI, but exercise made levodopa work better. Larger trials are testing whether vigorous exercise slows the disease. Work with a physical therapist.
Contains natural levodopa, so it can act like the drug, but doses in supplements vary widely. Never combine it with levodopa unless your neurologist supervises.
Low levels are common in Parkinson's and raise fall and fracture risk. It's reasonable to correct a measured deficiency.
Each was tested in large controlled Parkinson's trials and didn't slow the disease.
Be careful: protein-rich meals can block levodopa from being absorbed, so ask about timing your doses. Some supplements, like St. John's wort, can interact with MAO-B inhibitors. Tell your neurologist about everything you take.
Centers recognized for expertise in this condition, and communities of people living with it.
Named a Parkinson's Foundation Center of Excellence, as described in the Foundation's 2018 center series.
Redesignated a Parkinson's Foundation Centre of Excellence in 2026 after a June 2026 review, one of only two in the UK.
Named a Parkinson's Foundation Center of Excellence in the Netherlands, with a program for young-onset Parkinson's.
Added to the Parkinson's Foundation Center of Excellence network in July 2018.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
You don't have to face Parkinson's alone. These groups connect patients, families and caregivers with people who understand. Most are free.
The Parkinson's Foundation's online community, with groups for newly diagnosed, young-onset, caregiving and Spanish speakers.
Join ↗The Michael J. Fox Foundation's network for making connections, with 12,000+ members in 84 countries.
Join ↗A Parkinson's discussion group moderated by Mayo Clinic staff.
Visit group ↗Active discussion groups on treatments, research and daily life.
Visit forum ↗A free social network for people living with Parkinson's.
Join ↗The UK charity's forum, with sections for the newly diagnosed and for young-onset Parkinson's.
Visit forum ↗An open Reddit community for patients, families and caregivers.
Open on Reddit ↗Many local and online groups. This link searches Facebook (a login is required).
Search Facebook ↗Many groups have separate sections for young-onset Parkinson's, care partners and Spanish speakers. Local exercise and boxing groups can double as social support.
Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Think about your privacy, because Reddit and many forums are public, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Levodopa is used everywhere. The gaps show up with newer treatments: Japan approved the first stem-cell therapy, and several drugs reached patients abroad years before the U.S.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| LevodopaStandard | 1970 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Foslevodopa pumpAdvanced disease | 2024 | 2022 | Yes | 2023 | Yes | — | — | 2024 | — |
| Istradefylline"Off" episodes, add-on | 2019 | Not approved | — | — | 2013 | — | — | — | — |
| TavapadonD1/D5 agonist | 2026 | — | — | — | — | — | — | — | — |
| Amchepry (iPS cells)Advanced disease | — | — | — | — | 2026, conditional | — | — | — | — |
| BemdaneprocelStem-cell neurons | Phase 3 | — | — | — | Fast-track status | — | — | — | — |
The only approved cell-replacement therapy for Parkinson's anywhere. It's built on Kyoto University's iPS research, and treatment begins in Japan this fall. There's no U.S. filing yet.
The 24-hour under-the-skin levodopa pump reached European and Canadian patients about two years before FDA approval in October 2024.
An add-on pill for "off" episodes. Japan approved it six years before the U.S. Europe never did, after negative results in European trials.
Parkinson's starts when a protein called alpha-synuclein folds the wrong way, clumps, and spreads from cell to cell. The brain cells that make dopamine are especially vulnerable. By the time a tremor appears, many of them are already gone.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations exist to help families affected by Parkinson's pay for care and costs. Funds are limited and rules vary, so contact each one directly.
Grants for physical activities (up to £250), household items (up to £500) or specialist equipment (up to £1,500) for households with savings of £6,000 or less. The current round closes November 27, 2026; dates may change.
See the grants ↗A $400 hardship grant once every 12 months for approved applicants in financial difficulty. Funds are limited and given first come, first served.
See the fund ↗A $400 hardship grant once every 12 months for approved applicants in financial difficulty. Applications are reviewed on a rolling basis; funds are limited.
See the program ↗Helps families with financial need pay for in-home, adult day or short-stay respite care, and separately pays up to $600 a year toward Parkinson's medicines. Each case is reviewed individually.
See the programs ↗Pays part of the cost of respite caregivers through local Caregiver Resource Centers. Care partners can apply once every 12 months. The program runs on donations, so funds are limited.
See the program ↗Grants of up to $1,200 per family per year toward in-home respite care from approved licensed agencies, first come, first served. Check that the program is still taking applications.
See the program ↗Need-based Steady Hands grants of up to $1,000 toward Parkinson's-related costs such as copays and therapies, paid to the provider. Funds are limited.
See the grant ↗Grants of up to £1,000 per person per year toward respite care. Contact the scheme administrator before booking care.
See the scheme ↗Helps pay prescription copays or Medicare Part B premiums. The fund was listed as open on October 6, 2026, but funds can run out.
Check fund status ↗Helps pay copays, coinsurance, deductibles and insurance premiums. Listed as open on October 6, 2026; the general Parkinson's fund was closed.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
The natural-remedies ratings (exercise, caffeine, mucuna, vitamin D, and the CoQ10 / creatine / vitamin E / inosine trials) and the levodopa-protein interaction reflect the long-standing published trial record and standard clinical guidance. They don't yet have individual citations here. Expert care centers: Only the King's College Hospital designation was confirmed as recent; the others are from Parkinson's Foundation posts dated 2018 to 2019, and the Foundation's current center list could not be opened. Check the Foundation's global care network page for the current list. Financial help: checked October 6, 2026. The Parkinson Network of Mt. Diablo page still dates the program from 2023 and its forms from 2024, so its current status is unconfirmed; the Central Florida grant's county and income rules come from its application form; the Patient Advocate Foundation fund covers only home addresses in designated ZIP codes. Other APDA chapters (for example Minnesota, Connecticut, Rhode Island and Vermont) also run hardship funds.